NewAmsterdam Pharma (NAMS) Other Non-Current Assets (2022 - 2026)

NewAmsterdam Pharma has disclosed Other Non-Current Assets across 4 years of filings, most recently posting $2.6 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $2.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (changed N/A YoY), and the FY2023 annual result was $35000.0, down 77.56% from the prior year.
• Other Non-Current Assets came in at $2.6 million for Q1 2026 at NewAmsterdam Pharma, up from $8000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.6 million in Q1 2026 to a low of $101.27 in Q2 2023.
• The 4-year median for Other Non-Current Assets is $12000.0 (2024), against an average of $440708.4.
• Across the five-year window, Other Non-Current Assets surged 23396.85% in 2023 and soared 7799.68% in 2024, its largest moves.
• NewAmsterdam Pharma's Other Non-Current Assets stood at $148.96 in 2022, then soared by 23396.85% to $35000.0 in 2023, then sank by 77.14% to $8000.0 in 2024, then surged by 32212.5% to $2.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $2.6 million (Q1 2026), $8000.0 (Q2 2024), and $16000.0 (Q1 2024), per Business Quant data.